Orteronel Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (ELM-PC 4): A Double-Blind, Multicentre, Phase 3, Randomised, Placebo-Controlled Trial
Lancet Oncol 2015 Feb 17;[EPub Ahead of Print], F Saad, K Fizazi, V Jinga, E Efstathiou, PC Fong, LL Hart, R Jones, R McDermott, M Wirth, K Suzuki, DB MacLean, L Wang, H Akaza, J Nelson, HI Scher, R Dreicer, IJ Webb, R de WitFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.